| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
32,066 |
28,170 |
$4.57M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
22,967 |
19,194 |
$3.80M |
| 71045 |
Radiologic examination, chest; single view |
3,565 |
3,018 |
$548K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,449 |
3,177 |
$513K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
7,369 |
6,005 |
$512K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,246 |
2,648 |
$423K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
4,569 |
3,885 |
$320K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
7,863 |
6,572 |
$194K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
5,217 |
1,767 |
$180K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,132 |
2,557 |
$140K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
338 |
276 |
$133K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,984 |
2,562 |
$125K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
20,739 |
16,563 |
$111K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,317 |
1,156 |
$107K |
| 71046 |
Radiologic examination, chest; 2 views |
1,209 |
1,055 |
$102K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
717 |
660 |
$78K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,084 |
873 |
$72K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
11,588 |
9,332 |
$63K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
2,542 |
945 |
$55K |
| 73562 |
|
1,730 |
1,400 |
$48K |
| 97161 |
|
522 |
461 |
$44K |
| 36415 |
Collection of venous blood by venipuncture |
8,496 |
7,257 |
$34K |
| 95806 |
|
36 |
30 |
$23K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
447 |
371 |
$19K |
| 81001 |
|
7,780 |
6,526 |
$18K |
| 97162 |
|
212 |
179 |
$17K |
| 80053 |
Comprehensive metabolic panel |
2,307 |
1,808 |
$17K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
529 |
494 |
$13K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
97 |
97 |
$12K |
| 84484 |
|
1,333 |
901 |
$11K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
339 |
289 |
$7K |
| 73564 |
|
104 |
94 |
$5K |
| 97113 |
|
132 |
50 |
$4K |
| 83690 |
|
1,045 |
870 |
$4K |
| 80076 |
|
623 |
526 |
$4K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
105 |
57 |
$4K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
50 |
40 |
$4K |
| 84703 |
|
581 |
516 |
$4K |
| 81025 |
|
720 |
599 |
$3K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
163 |
112 |
$3K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
69 |
69 |
$3K |
| 73502 |
|
60 |
50 |
$2K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
43 |
37 |
$1K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
247 |
217 |
$932.31 |
| 80061 |
Lipid panel |
81 |
79 |
$717.07 |
| 87276 |
|
77 |
46 |
$390.71 |
| 87275 |
|
77 |
46 |
$354.80 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
22 |
12 |
$307.01 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
14 |
12 |
$219.24 |
| 84702 |
|
12 |
12 |
$124.09 |
| 83605 |
|
16 |
12 |
$114.51 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
33 |
25 |
$84.06 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
33 |
25 |
$84.06 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
278 |
248 |
$0.00 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
149 |
63 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
52 |
39 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,074 |
1,596 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
55 |
19 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
47 |
30 |
$0.00 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
12 |
12 |
$0.00 |